Fig. 5

Kaplan-Meier plot of the Mannheim cohort of OS and DFS associated with MIR31HG and its splice variants risk stratification. No significant correlation was found with OS (a, median survival 18 vs. 21 months) and DFS (b, median survival 11 vs. 9 months for MIR31HG) in the group with full-length transcript of MIR31HG. The group with high MIR31HGΔE1 expression showed a worse OS (c, median survival 15 vs. 38 months) and DFS (d, median survival 7 vs. 25 months) compared to the group with low expression. The group with high MIR31HGΔE3 expression showed a worse OS (e, median survival 12 vs. 30 months) and DFS (F, median survival 9 vs. 15 months) compared to the group with low expression. The numbers below the figures showed the number of patients at risk in each group